- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03825757
Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical) (AirGOs-med)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomization and the treatment arms I-II: The patients are randomized to two treatment arms I) ASA- desensitization po tablet daily for 11 months (n=36) II) Placebo po tablet daily for 11 months (n=18).
ASA challenge and desensitization (Primaspan) /Placebo: is conducted according to modified international protocol. FEV1 should be at least 1.5 L and > 60% of predicted before challenge or desensitization. On the first day every patient will receive 25 mg + 25 mg ASA at a hospital setting. On the second day every patient will receive 50 mg + 25 mg ASA at a hospital setting. On the third day every patient will receive 75 mg + 25 mg ASA at a hospital setting. On the fourth day every patient will receive 100 mg + 25 mg ASA at a hospital setting.
During the ASA challenge, patient who is ASA-challenge positive is then randomized and starts the trial so that he/she uses blinded ½ tablet of 250 mg ASA or ½ tablet of placebo daily at home for the next 1 month. After this period of 1 month, the dosing is increased at hospital setting, so that the patient receives blindly 250 mg ASA 1/2 tablet + 1/2 tablet or placebo 1/2 tablet + 1/2 tablet. Thereafter he/she will continue using blindly 250 mg ASA 1 tablet or placebo 1 tablet daily at home for the next 10 months. If the patient does not tolerate the up-dosing of ASA/placebo, he/she will continue using blindly ½ tablet of 250 mg ASA/placebo daily at home for the next 10 months. The total duration of the ASA/placebo treatment is 11 months. We additionally take nasal, blood and urine samples during the trial.
Follow-ups. The symptom questionnaire and interview of side-effects are performed during each visit. Lung function (eNO, nNO, PEF, spirometry) is monitored and the patient will visit doctor and/or nurse at 1, 5, 11, and 12 months post-starting with the treatment. Samples are taken during recruitment visit, before and after ASA-challenge and at 5, 11 and 12 months post-starting with the treatment. We also monitor side-effects, exacerbations, need of medication (po. cortisocteroids; antibiotics) and satisfaction to treatment.
Primary end point is change in nasal endoscopic nasal polyp score at -4 days vs. +11 months post-randomization. Secondary end point is change in Sinonasal Outcome Test -22 (SNOT-22) score at -4 days vs. +11 months post-randomization, and change in relative Forced expiratory volume in 1 second (FEV1 %) without bronchodilator at -1 month vs. +11 months post-randomization.
Safety (complications, adverse effects), costs and loss of productivity between study arms will be compared.
Trial medication will be discontinued, if surgery is needed before the end of follow-up.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sanna Toppila-Salmi, MD PhD
- Phone Number: +358505431421
- Email: sanna.salmi@helsinki.fi
Study Contact Backup
- Name: Annina Lyly, MD PHD
- Phone Number: +358505455051
- Email: annina.lyly@hus.fi
Study Locations
-
-
-
Helsinki, Finland, 00029
- Helsinki University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: ALL these need to be positive:
- Endoscopic nasal polyp score ≥4
- SNOT-22 ≥30
- Sinus Computed tomography Lund-Mackay score ≥14. The new sinus CT scans are needed if the previous sinus CT scans have been performed over 36 months before recruitment visit or if there is a suspicion of complication of CRS (f.ex. mucocele, invasive fungal rhinosinusitis)
- ≥1 previous partial/total ethmoidectomy surgery.
In addition, patient should have a history of at least one of the following:
>1 oral corticosteroids during the past two years >3 antibiotic courses during the past two years. In patients with contraindication/adverse effects in using oral steroids additional criteria are not required.
Exclusion Criteria:
- complication of CRS (f.e. mucocele, invasive fungal rhinosinusitis)
- bleeding diathesis
- pregnancy/ breastfeeding
- cystic fibrosis
- primary ciliary dyskinesia (PCD)
- sarcoidosis
- granulomatosis with polyangitis (GPA)
- eosinophilic granulomatosis with polyangitis (EGPA)
- immunosuppression (diagnosed Spesific antibody deficiency (SAD), CVI, HIV
- use of biologicals/immunosuppressive medication
- immunotherapy
- Daily use of systemic corticosteroids (Prednisolon 10mg or equivalent) -communication problems (f.e. neurological/psychiatric disease, language skills) -unlikely to comply
- other severe disease
- uncontrolled asthma
- ASA-challenge negative
- gastric ulcer
- anticoagulant treatment
- SSRI-depression medication
- beta-blocker
- severe chronic urticaria
- ASA anaphylaxis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Primaspan tablet 250 mg
Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months.
If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
|
Primaspan 250 mg tablet Acetyl Salicylic Acid
Other Names:
|
Placebo Comparator: Placebo tablet
Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months.
If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
|
Placebo Oral Tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in endoscopic Nasal polyp score of both sides of the nasal cavity.
Time Frame: at -4 days vs. at 11 months post-randomization
|
Change means differences between at time -4 days versus (vs.) at time +11 months post-randomization.
Minimum value is 0. Maximum value is 8.
A higher score means worse outcome.
|
at -4 days vs. at 11 months post-randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Sinonasal outcome test 22 (SNOT22). Validated nose-specific quality of life questionnaire, 0-110 points.
Time Frame: at -4 days vs. at 11 months post-randomization
|
Change means differences between at time -4 days vs. +11 months post-randomization.
A higher score means worse outcome.
|
at -4 days vs. at 11 months post-randomization
|
Change in the Relative forced expiratory volume in 1 second (FEV1%) without bronchodilator.
Time Frame: at -1 month vs. at 11 months post-randomization
|
Change means differences between at time -1 month vs. +11 months post-randomization.
A higher value means better outcome.
FEV1% is measured by Spirometry.
|
at -1 month vs. at 11 months post-randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sanna Toppila-Salmi, MD PhD, Helsinki University Central Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Inflammation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Dermatologic Agents
- Antifungal Agents
- Keratolytic Agents
- Aspirin
- Salicylic Acid
- Salicylates
Other Study ID Numbers
- TYH2018203
- 2017-001570-42 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rhinosinusitis (Diagnosis)
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
Johns Hopkins UniversityGlaxoSmithKlineRecruitingChronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
Washington University School of MedicineCompletedChronic Rhinosinusitis (Diagnosis) | Allergic Rhinosinusitis | Chronic Eosinophilic RhinosinusitisUnited States
-
Lyra TherapeuticsRecruitingChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Poland, Bulgaria, Belgium, Germany, Hungary
-
Medical University of ViennaRecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Nasal Polyps | Chronic Rhinosinusitis With Nasal PolypsAustria
-
Sohag UniversityNot yet recruitingRhinosinusitis Chronic | Rhinosinusitis | Fungal Sinusitis | Rhinosinusitis Acute | Allergic Fungal Rhinosinusitis | Intracranial Extension | Invasive Fungal Sinusitis (Diagnosis)Egypt
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
Oticara Australia PTY LTDRecruitingChronic Rhinosinusitis (Diagnosis)Australia
-
Intersect ENTCompletedChronic Rhinosinusitis (Diagnosis)United States
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Rhinosinusitis (Diagnosis)United States
Clinical Trials on Placebo Oral Tablet
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
University of OxfordNovo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United Kingdom
-
Fulcrum TherapeuticsTerminated
-
EicOsis Human Health Inc.CompletedHealthy AdultsUnited States
-
The Mind Research NetworkTerminatedSmoking Cessation | Tobacco Use DisorderUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis CChina